OncRef

Clinical Trial: NCT00740805

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-08-19

Study Overview

Brief Summary

This phase I trial studies the side effects and best dose of veliparib, cyclophosphamide, and doxorubicin hydrochloride when given together in treating patients solid tumors or non-Hodgkin lymphoma that has spread to other areas of the body or cannot be removed by surgery. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, cyclophosphamide, and doxorubicin hydrochloride may kill more cancer cells.

Official Title

A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma

Conditions

Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Neoplasm

Intervention / Treatment

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Drug: Veliparib

Other Study ID Numbers

  • NCI-2009-00262
  • NCI-2009-00262
  • CDR0000600234
  • 050803
  • 050803
  • 7998
  • P30CA072720
  • U01CA132194
  • U01CA099118
  • UM1CA186716

Start Date (Actual)

2008-08-18

Primary Completion Date (Actual)

2021-09-03

Study Completion Date (Estimated)

2026-10-22

Enrollment (Actual)

81

Study Type

Interventional

Phase

Phase 1